Trial abstract · §3
RETA-PH2-T2D — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 36 | Reduction of up to 2.02 percentage points versus 0.01 with placebo | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Retatrutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 35.0 | 13.0 | Phase 2 obesity trial (12 mg, 48 weeks) |
| Diarrhoea | 29.0 | 9.0 | Phase 2 obesity |
| Vomiting | 24.0 | 2.0 | Phase 2 obesity |
| Constipation | 20.0 | 9.0 | Phase 2 obesity |
| Increased heart rate | — | — | Dose-dependent rise of approximately 6–10 beats/min at higher doses, attenuating by week 24 |
| Discontinuation for adverse events | 16.0 | 4.0 | Phase 2 obesity (highest dose cohort) |
Compound Evidence Institute · CEI-TR-0037/3 · https://compoundevidence.com/trials/reta-ph2-t2d/results/ · retrieved 30 July 2026